CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 829 enrolled
Drug / intervention
Coumarin/troxerutin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01848210
NCT01848210Phase 4Completed
CompareCT.gov

Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT

Takeda·interventional·Posted May 7, 2013·Updated Nov 11, 2016

In Brief

A Phase 4 clinical trial evaluating Coumarin/troxerutin and Placebo for Chronic Venous Insufficiency. Completed, enrolled 829 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of the fixed-dose combination of coumarin and troxerutin versus placebo in the symptomatic treatment of chronic venous insufficiency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Venous Insufficiency
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2013
Enrollment StartMay 1, 2013
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.2 years ago

Interventions

Coumarin/troxerutindrug

Coumarin + troxerutin fixed-dose combination tablets

Placebodrug

Coumarin + troxerutin placebo-matching tablets